Non-linearity in the cost-effectiveness frontier

Health Economics

Volumn 15, Issue 6, 2006, Pages 565-577

  Lord, Joanne ^a   Laking, George ^b   Fischer, Alastair ^c  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cost effectiveness analysis; Decision rules; Expansion path; Non linearity; Resource allocation

Indexed keywords

ARTICLE; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; LINEAR SYSTEM; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; GREAT BRITAIN; HUMANS; MODELS, ECONOMETRIC; RESOURCE ALLOCATION; STATE MEDICINE;

EID: 33745294929     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1083     Document Type: Article

References (27)

1. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ 1993; 12: 459-467.
2. Birch S, Gafni A. Cost effectiveness/utility analysis. Do current decision rules lead us to where we want to be? J Health Econ 1992; 11: 279-296.
3. Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. J Health Econ 1993; 12: 469-476.
4. Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Can Med Assoc J 1993; 148: 913-917.
5. Donaldson C, Currie G, Mitton C. Cost effectiveness analysis in health care: contraindications. Br Med J 2002; 325: 891-894.
6. Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003; 21: 149-157.
7. Oliver A. Accounting for the missing opportunity costs in incremental cost-outcome analysis. Appl Health Econ Health Policy 2002; 1: 191-196.
8. Towse A, Pritchard C, Devlin N (eds). Cost-effectiveness Thresholds: Economic and Ethical Issues. Office of Health Economics: London, 2002.
9. Elbasha EH, Messonnier ML. Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale. Health Econ 2004; 13: 21-35.
10. Stevens W, Normand C. Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation. Soc Sci Med 2004; 58: 315-320.
11. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479-500.
12. Coyle D, Buxton M, O'Brien BJ. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Econ 2003; 12: 421-427.
13. Palmer S, Smith PC. Incorporating option values into the economic evaluation of health care technologies. J Health Econ 2000; 19: 755-766.
14. Alvarez LHR, Stenbacka R. Adoption of uncertain multi-stage technology projects: a real options approach. J Math Econ 2001; 35: 71-97.
15. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-1293.
16. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; VIII: 283-298.
17. Phelps CE, Mushlin AI. Focusing medical technology assessment using medical decision theory. Med Decis Making 1988; 8: 279-289.
18. Ubel PA, Jepson C, Baron J, Hershey JC, Asch DA. The influence of cost-effectiveness information on physicians' cancer screening recommendations. Soc Sci Med 2003; 56: 1727-1736.
19. Marshall T, Rouse A. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. Br Med J 2002; 325: 197-203.
20. Lord J, Laking G, Fischer A. Optimal diagnosis: direct estimation of expansion curves in cost-effectiveness space. Health Economists Study Group Meeting, Glasgow, 2004.
21. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452.
22. Phelps CE, Mushlin AI. On the (near) equivalence of cost-effectiveness and cost-benefit analysis. Int J Technol Assess Health Care 1991; 7: 12-21.
23. Johannesson M. The relationship between cost-effectiveness analysis and cost-benefit analysis. Soc Sci Med 1995; 41: 483-489.
24. Brouwer WBF, Koopmanschap MA. On the economic foundations of CEA. Ladies and gentlemen, take your positions! J Health Econ 2000; 19: 439-459.
25. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341-364.
26. Ben-Zion U, Gafni A. Evaluation of public investment in health care. Is the risk irrelevant? J Health Econ 1983; 2: 161-165.
27. Ament A, Baltussen R. The interpretation of results of economic evaluation: explicating the value of health. Health Econ 1997; 6: 625-635.